Video

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab

Author(s):

Michael Atkins, MD,Evan Lipson, MD

Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.

Related Videos
Thach-Giao Truong, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Related Content
RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com
November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Lung Cancer
November 11th 2024

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

Todd Schlesinger, MD, FAAD, FASMS
November 1st 2024

Ameluz-PDT Leads to Target Lesion Clearance in Superficial Basal Cell Carcinoma